Anti-bag3 antibodies for therapeutic use

Abstract

The present invention relates to the use of BAGS antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.

1 - 16 . (canceled) 
     
     
         17 . A method for treating neoplastic diseases, inflammatory diseases, immune diseases and/or degenerative diseases, comprising administering an anti-BAG3 antibody to a subject in need thereof, wherein BAG3 protein is soluble. 
     
     
         18 . The method according to  claim 17 , wherein said neoplastic disease is pancreatic tumor. 
     
     
         19 . The method according to  claim 17 , wherein said neoplastic disease is bladder tumor. 
     
     
         20 . The method according to  claim 17 , wherein said anti-BAG3 antibody is a polyclonal antibody. 
     
     
         21 . The method according to  claim 17 , wherein said anti-BAG3 antibody is a monoclonal antibody. 
     
     
         22 . The method according to  claim 21 , wherein said monoclonal antibody is a murine antibody, a humanized antibody, a chimeric antibody, a recombinant antibody, a conjugated antibody, an scFv fragment, a Fab fragment or a F(ab′)2 fragment. 
     
     
         23 . The method according to  claim 22 , wherein said scFv fragment is diabody, triabody or tetrabody. 
     
     
         24 . The method according to  claim 22 , wherein said monoclonal antibody is produced by at least one of the nine mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8 and AC-9. 
     
     
         25 . The method according to  claim 24 , wherein said monoclonal antibody is produced by at least one of the five mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, and AC-5. 
     
     
         26 . The method according to  claim 22 , wherein said monoclonal antibody is produced by at least one of the following clones: AC-rb1, AC-rb2, AC-rb3, or AC-rb4, and by at least one of the following subclones: AC-rb1a, AC-rb1b, AC-rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC-rb4a, or AC-rb4b. 
     
     
         27 . A pharmaceutical composition comprising at least one anti-BAG3 antibody and at least one pharmaceutically acceptable excipient, wherein the BAG3 protein is soluble. 
     
     
         28 . The pharmaceutical composition according to  claim 27 , wherein said anti-BAG3 antibody is a monoclonal antibody produced by at least one of the nine mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8 and AC-9. 
     
     
         29 . The pharmaceutical composition according to  claim 27 , wherein said anti-BAG3 antibody is a monoclonal antibody produced by at least one of the five mother clones selected from the group consisting of: AC-1, AC-2, AC-3, AC-4, and AC-5. 
     
     
         30 . The pharmaceutical composition according to  claim 27 , wherein said composition is formulated in a form suitable for oral administration, parenteral administration, or topical administration. 
     
     
         31 . The pharmaceutical composition according to  claim 30 , wherein said form suitable for oral administration is selected from the group consisting of tablets, capsules, solutions, suspensions, granules, and oily capsules. 
     
     
         32 . The pharmaceutical composition according to  claim 30 , wherein said parenteral administration is intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic administration. 
     
     
         33 . The pharmaceutical composition according to  claim 30 , wherein said form suitable for topical administration is cream, salve, ointment, or gel. 
     
     
         34 . The pharmaceutical composition according to  claim 30 , wherein said form suitable for parenteral administration is an aqueous buffer solution or an oily suspension.